Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia.

Sixi Wei; Yating Wang; Qixiang Chai; Qin Fang; Yaming Zhang; Yinghao LU; Jishi Wang

Return

Over-expression of heme oxygenase-1 in peripheral blood predicts the progression and relapse risk of chronic myeloid leukemia.

Author: Sixi WEI ^{1
,

2} ; Yating WANG ³ ; Qixiang CHAI ³ ; Qin FANG ⁴ ; Yaming ZHANG ³ ; Yinghao LU ³ ; Jishi WANG ⁵
Author Information

1. Hematopoietic Stem Cell Transplantation Center of Guizhou Province, Department of Hematology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China
2. Department of Clinical Biochemistry, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China.
3. Hematopoietic Stem Cell Transplantation Center of Guizhou Province, Department of Hematology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China.
4. Department of Pharmacy, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China.
5. Hematopoietic Stem Cell Transplantation Center of Guizhou Province, Department of Hematology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou 550004, China. Email: wangjishi9646@163.com.
Publication Type:Journal Article
MeSH: Bone Marrow; metabolism; Female; Flow Cytometry; Gene Expression; Heme Oxygenase-1; blood; genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; diagnosis; enzymology; pathology; Male; Predictive Value of Tests; Real-Time Polymerase Chain Reaction
From: Chinese Medical Journal 2014;127(15):2795-2801
CountryChina
Language:English
Abstract:
BACKGROUNDThere are limited eligible clinical markers at present to monitor the progress of chronic myeloid leukemia (CML). Heme oxygenase-1 (HO-1), as one of the most important oxidation-regulating enzymes in vivo, suggests the onset and progression of cancer when highly expressed. Furthermore, HO-1 level is related with the occurrence and development of hematological diseases. But the relationship between HO-1 expression and progression/relapse of CML has seldom been studied hitherto. This study aimed to investigate the relationship between them to find out a new molecular marker for prediction.
METHODSA total of 60 peripheral blood and bone marrow (BM) samples from 25 CML patients in different phases were collected respectively to detect the expressions of HO-1 and bcr/abl using real-time PCR. Routine blood test was performed to detect the changes of leukocyte and platelet counts. The proportion of primitive cells in BM was detected by flow cytometry. The relationship between high HO-1 expression and CML progression and relapse was explored by the analysis of variance by Wilcoxon test and linear regression analysis. The diagnostic accuracy and cutoff values were determined by receiver operating characteristic curve.
RESULTSRelative expression of HO-1 mRNA in CML patients peripheral blood was significantly higher than that of donors (P < 0.0001), which were 0.57±3.78 and (1.417±1.125)×10(-6), respectively. HO-1 expression level in CML patients was 0.061 5±0.062 4, which decreased to 0.009 4±0.006 7 upon CMoR, and remained remarkably higher 0.016 3±0.017 5 than that of normal donors (1.417±1.125)×10(-6), P < 0.001. When relapse occurred, HO-1 expression significantly increased from 0.020 6±0.021 0 to 3.852±10.285 in CMoR stage and undergoing relapse. According to progression of CML, HO-1 expression level in CML patients increased from CP (0.009 5±0.017 6) to AP (0.028 0±0.055 7) and then to BP (0.276 7 ± 0.447 0). And there was a linear correlation between HO-1 expression and proportion of primitive CML cells. The diagnostic accuracies and cutoff values of HO-1 expression for CML-CP, CML-AP, and CML-BP were 1.0, 0.748, and 0.965, respectively, as well as 0.000 070, 0.001 917, and 0.020 696, respectively.
CONCLUSIONHO-1 may be a potential molecular indicator for the progression and relapse of CML.